| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 14,531 |
| Net loss | -63,189 |
| Prepaid expenses and other current assets | -2,173 |
| Other long-term liabilities | 21 |
| Other long-term assets | 0 |
| Operating lease liabilities | 1,384 |
| Income tax receivable | -31,975 |
| Accrued expenses | -2,360 |
| Accounts receivable | 1,687 |
| Accounts payable | -588 |
| Loss on disposal of property and equipment | -6 |
| Depreciation and amortization expense | 3,302 |
| Amortization of premiums on marketable securities | -1,461 |
| Non-cash royalty revenue | 2,020 |
| Non-cash interest associated with the sale of future royalties | -1,399 |
| Operating lease, right-of-use assets | -3,607 |
| Net cash used in operating activities | -12,783 |
| Proceeds from maturities and sale of marketable securities | 190,497 |
| Purchase of property and equipment | 11,438 |
| Purchase of marketable securities | 141,008 |
| Net cash provided by investing activities | 38,051 |
| Proceeds from the exercise of stock options | 94 |
| Payments for settlement of share-based awards | 267 |
| Payments on royalty sale liability, net of imputed interest | 18,124 |
| Net cash used in financing activities | -18,297 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 6,971 |
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)